Novo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027

Core Viewpoint - Novo Nordisk plans to reduce the U.S. list prices of its weight-loss drug Wegovy by up to 50% and diabetes drug Ozempic by 35% starting January 2027 [1] Company Actions - The price cut for Wegovy will be up to 50% [1] - The price reduction for Ozempic will be 35% [1] Market Impact - The decision is expected to influence the accessibility and affordability of these medications in the U.S. market [1]